12:00 AM
Mar 18, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Perifosine: Development discontinued

Aeterna Zentaris discontinued development of perifosine to treat MM after a pre-planned interim analysis of a double-blind, international Phase III trial by an independent DSMB showed that once-daily 50 mg oral perifosine plus Velcade bortezomib and dexamethasone was unlikely to meet the primary endpoint of improving PFS vs. placebo plus Velcade and dexamethasone. No safety concerns were identified. The trial had planned to enroll about 450 patients with MM who relapsed on a prior Velcade treatment regimen. The company had an SPA from FDA for the trial. Last year, Aeterna reported that...

Read the full 448 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >